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individual level by logistic regression. Results: At the time of the survey, 19.5% 
of the Portuguese population with ages between 50 and 64 years old were officially 
retired. A larger average number of major chronic diseases per capita was found 
among those with early retirement when compared to active workers in the same 
range of age (2.0 vs. 1.4 p< 0.001). RD were particularly prevalent among early retirees 
when compared with employees (43.3% vs. 32.1%, p< 0.001). The following OR and 
PAF (adjusted by age, sex and region and unadjusted) were obtained: RD (OR:1.3-
1.4; PAF:7.3-9.7), chronic pain (OR:1.4-1.4; PAF:6.6-7.2), hypertension [OR:1 (NS) 
-1.3; PAF:1.1-7.1], diabetes [OR:1 (NS) -1.2 (NS); PAF:0-2.4], renal impairment (OR:3.3 
-3.4; PAF:2.7-3.2), respiratory diseases (OR:1.5-1.7; PAF:1.5-2.1), stroke (OR:3.2-3.6; 
PAF:2.6-3.2), myocardial infarction [OR:1.2 (NS) -1.9; PAF:0.3-1.1], cancer (OR:2.1-
1.9; PAF:2.1-2.1), depression (OR:1.5-1.2 (NS); PAF:4.8-2.8) and anxiety (OR:1.6-1.5; 
PAF:3.7-3.5) with NS standing for not statically significant. ConClusions: From a 
public health angle, PAF is a good measure of the importance of a risk factor, taking 
into account both the strength of the association with the outcome and its preva-
lence in the population. Among all major chronic diseases, RD had the highest PAF 
estimates for early retirement in Portugal.
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objeCtives: To assess cost of pharmacotherapy in Polish patients with rheu-
matoid arthritis (RA) in relation to disease activity (DAS28-CRP) and disability 
(HAQ-DI). Methods: Data on drug consumption was collected during a prospec-
tive one center cohort observational study of non-selected RA patients discharged 
from tertiary academic hospital. At enrollment patients were divided according 
to DAS28-CRP and HAQ-DI. Observational period was 6 months. Spearman rang 
correlation coefficient and test of its significance were used to investigate the rela-
tionship of cost of pharmacotherapy with disease activity and disability. Mean total 
cost of drugs and mean cost of drugs covered by public payer were calculated in 
PLN at 2014 prices (1 EURO= 4.2 PLN in 2014). Results: DAS28-CRP was ≤ 5.1 in 124 
patients (group A) and > 5.1 in 83 patients (group B). HAQ-DI was > 2 in 51 patients 
(group I), > 1 and ≤ 2 in 88 patients (group II), ≤ 1 in 66 patients (group III). Mean cost 
of pharmacotherapy per patient was 1010 PLN in group A and 858 PLN in group B, 
1078 PLN in group 1, 981 PLN in group II and 745 in group III. The differences between 
groups were not statistically significant. Public payer covers only 36-40% of the drugs 
cost. ConClusions: These results represent the current use of drugs in the popu-
lation of Polish RA patients under real-life conditions and indicate that there is no 
impact of disease activity and disability on the cost of pharmacotherapy due to RA.
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objeCtives: In the light of future arrival of subcutaneous (SC) formulation of 
tocilizumab for the treatment of moderate to severe active rheumatoid arthritis, 
a multidimensional analysis has been performed in order to evaluate potential 
impact of introducing SC formulation vs. intra-venous (IV) one from the perspective 
of both patients and hospitals in Italy. Methods: The analysis was conducted in 
three Italian Rheumatology centers (AO-S. Anna-Ferrara, AO-Verona, UOS-Valeggio-
sul-Mincio) through a questionnaire administered to clinicians and nurses. A 60 
minutes day-hospital administration for IV and 20 seconds-1 minute administration 
for SC selfinjector or pre-filled syringe administered at home (excluding the first 
administration) were assumed. Monitoring visits were considered as 1 per month 
for IV and 1 every three months for SC. Four impact areas were evaluated: patient’s 
drug-administration time and costs (including transportation time and cost and loss 
of productivity), drug-administration related hospital-personnel time, drug wastage 
and patient risk profile evaluated through Failure Models and Effect Analysis. A one 
year time horizon was considered. Results: The analysis showed that the new SC 
formulation, compared to IV, could have a significant impact in terms of: patient 
time saving (- 91% of the time for the administration of therapy), patient costs 
(-86%), clinicians and nurses time saving measured as Full Time Equivalent (- 59% 
for clinicians and -94 % for nurses), drug wastage (-100%), and patient risk profile 
(-93%). ConClusions: The subcutaneous formulation of tocilizumab could have 
several organizational and management impacts. From the hospital perspective it 
could lead to reduction of medical resources consumption with the possibility to 
re-allocate them in other medical activities. From the patient perspective the new 
SC formulation could lead to time savings and costs reduction with a potential 
improvement of patient quality of life.
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objeCtives: Conduct a systematic review and meta-analysis of published litera-
ture on persistence with denosumab in patients with osteoporosis. Methods: 
Ps patients had dominantly (54%) low disease activity, in RA group mostly (51%) the 
moderate activity was observed, while the most frequent disease activity category 
for CD patients was remission (39%). Mean annual cost of overall work impairment 
(presenteeism and absenteeism cost together) amounted to PLN 29 727 for RA, PLN 
24 434 for Ps and PLN 23 682 for CD. Cost of loss of productivity due to RA ranged 
from PLN 15 069 for patients in remission to PLN 41 296 for highly active disease. For 
Ps it was respectively PLN 13 846 and PLN 44 009 and for CD PLN 15 543 and PLN 63 
771. ConClusions: Productivity loss among workers with CD, Ps and RA generates 
significant costs for society which rises with disease activity.
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objeCtives: To estimate the long-term productivity costs (PC) and their determinants 
associated with absenteeism and permanent work disability (WD) in Finnish patients 
with early rheumatoid arthritis (RA) available to workforce at baseline. Methods: 
A cohort of subjects with early RA was created by identifying the new cases of RA 
from the national register of the Social Insurance Institution (SII) in Finland, who 
were granted a special reimbursement of anti-rheumatic medications for rheumatoid 
factor positive (ICD-10 code: M05) or negative RA (M06) in 2000 – 2007. The obtained 
dataset was enriched by cross-linking with the national databases about the sub-
jects’ annual incomes, WD days, and permanent disability pensions. The human 
capital approach was applied to estimate PC based on subjects’ the annual number of 
absenteeism days and incomes. The PC were estimated and expressed as per patient-
observation year. Hurdle regression analysis was applied to study the determinants 
of PC. Sensitivity analyses were conducted to test the robustness of the obtained 
results. Results: The study cohort comprised 7,831 subjects with early RA in paid 
jobs. The mean age (SD) of subjects was 46 years (11) and 71 % were women. Mean 
(bootstrapped 95%CI) annual PC per patient-observation year was 4,574€ (95% CI 
4,469€ to 4,680€ ). The PC increased progressively over the years. The use of metho-
trexate-based combination therapies during the first three months after RA diagnosis 
reduced significantly the cumulative PC during the follow-up. ConClusions: So 
far the majority of the productivity cost studies have been based on cross-sectional 
data. However, the results of the present study provide unique evidence about the 
longitudinal economic burden of RA over the course of disease. The results highlight 
the need for treatment strategies with predefined targets and tight control of disease 
activity in the early course of disease to reduce the long-term burden of RA.
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objeCtives: To study the trends in work productivity loss pre- and post-diagnosis 
of incident rheumatoid arthritis (RA) and compare it to patients with osteoarthritis 
(OA) undergoing knee or hip replacement surgery. Methods: Retrospective register 
study conducted using Swedish national registers. Patients of working age with an 
incident diagnosis of RA between 2003 and 2009 were identified in the National 
Patient Register (n= 14900). OA patients undergoing surgery were identified during 
the same period and considered as a reference group (n= 34240). Monthly productiv-
ity loss twelve months pre-diagnosis to twelve months post-diagnosis was evaluated 
in the base case. Productivity loss was defined as the sum of net sick leave days and 
net disability pension days as recorded in the Social Insurance Register. Results: 
Monthly productivity loss gradually increased during the months leading up to RA 
diagnosis, peaking the month after diagnosis (mean 14.7 days/month). The same 
pattern was observed in the OA group in relation to time of surgery, although the 
increase in productivity loss the months post-surgery was considerably larger than 
the corresponding increase in the RA patients, peaking the second month following 
surgery (28.5 days/month). Twelve months post-surgery, the OA patients returned 
to levels of productivity loss similar to those seen six months pre-surgery (12.3 
days/month vs. 12.7 days/month, respectively). This reversal was not mirrored by 
the RA patients, who stabilized at an elevated level of productivity loss post- com-
pared to pre-diagnosis levels (12.1 days/month vs. 9.6 days/month). ConClusions: 
This study illustrates the unmet needs in RA. The partial reversal in work ability 
post-diagnosis, in contrast to the almost complete reversal seen in OA patients 
post-surgery, highlights the need for improved treatment options in RA; while the 
gradual loss of work ability leading up to diagnosis highlights the need for interven-
tion earlier in the disease process.
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objeCtives: Chronic diseases and in particular rheumatic diseases (RD) may lead 
to early retirement, generating substantial indirect costs to society. We compare 
RD to other major chronic diseases regarding their impact on the likelihood of 
early retirement in the Portuguese population. Methods: The study population 
consisted of all people between 50 and 64 years of age (3,762 men and 4,241 women) 
who participated in the Portuguese National Health Survey, conducted in 2005/2006. 
Self-reported data were collected on health, sociodemographic and occupational 
factors. The effects of RD and other chronic diseases on the likelihood of early retire-
ment and the population attributable fractions (PAF) estimates were obtained at the 
